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LongitudinalWeestimated the progression of brain atrophy and cerebrovascular lesions onMRI in a prospective cohort of pa-
tients with various manifestations of arterial disease. Within the SMART-MR study, using brain MRI data from
baseline and after on average 3.9 years of follow-up, intracranial volume (ICV), total brain, cortical gray matter,
ventricular, white matter lesion volumes and visually rated infarcts were obtained from 663 patients (mean age
57 ± 9 years, 81% men).
Global and cortical atrophy increased quadratically with age. Men showed more progression of global and cortical
atrophy than women (mean difference in change (95% CI):−0.25 (−0.44;−0.06) and−0.94 (−1.35;−0.52)%
ICV) and had an increased risk of new brain infarcts (OR = 2.7, 95% CI 1.2–6.1). Compared with coronary artery
disease patients, cerebrovascular disease patients showed more progression of cortical and subcortical atrophy
and an increased risk of new brain infarcts, and peripheral arterial disease patients showed more progression
of cortical atrophy. These results were independent of cerebrovascular lesions and cardiovascular risk factors.
In patients with manifest arterial disease, brain atrophy tended to accelerate with older age and men had more
progression of brain atrophy and cerebrovascular lesions thanwomen. Additionally, patients with cerebrovascu-
lar and peripheral arterial disease showed the most prominent progression of atrophy and lesions.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Cardiovascular disease is a major health problem worldwide, with
coronary artery disease and stroke as the leading causes of morbidity
and mortality. Improved possibilities to treat cardiovascular disease
have led to increased survival rates of patients with cardiovascular dis-
ease. However, this has resulted in reduced health status and higher
rates of functional disabilities in these aging patients [1].
In patients with cardiovascular disease, cerebrovascular lesions –
such as brain infarcts and white matter lesions – and brain volume
loss are common ﬁndings on magnetic resonance imaging (MRI) [2].
This is of clinical importance since it has been shown that the extent
and rate of progression of these brain abnormalities increase the risk
of cognitive and functional decline [3–5].
Also, evidence has accumulated that cardiovascular risk factors and
disease play an important role in the etiology of cerebrovascular lesionstrecht, Julius Center for Health
X 85500, 3508 GA, Utrecht,
8099.
lings).
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ights reserved.and brain atrophy [6–8] and it can therefore be suggested that persons
with high vascular risk are more prone for accelerated brain aging.
However, the effect of vascular disease present at various locations is
not well studied.
In the general population, longitudinal studies have shown that loss
of brain volume and accumulation of cerebrovascular lesions start at a
slow rate in early adulthood and accelerate in older age [5,6,9–11].
However, to the best of our knowledge, no longitudinal studies have
been performed in a population with vascular disease.
We estimated the rate of progression of brain atrophy and cere-
brovascular lesions on MRI over on average 3.9 years of follow-up
in a large cohort of patients with manifest arterial disease at various
locations.2. Methods
2.1. SMART-MR study
Data were used from the SecondManifestations of ARTerial disease-
Magnetic Resonance (SMART-MR) study, a prospective cohort study
aimed at investigating brain changes on magnetic resonance imaging
(MRI) in independently living patients with manifest arterial disease.
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[2,12]. In brief, between May 2001 and December 2005, all patients,
from both hospitalized inpatients and outpatient clinics, newly referred
to the University Medical Center Utrecht with manifest arterial disease,
such as coronary artery disease (CAD), cerebrovascular disease (CVD),
peripheral arterial disease (PAD), and/or an abdominal aortic aneurysm
(AAA), and without MR contraindications, were invited to participate.
CAD was deﬁned as myocardial infarction, coronary artery bypass
graft surgery, or percutaneous transluminal coronary angioplasty in
the past or at inclusion. Patients with a transient ischemic attack or
stroke at inclusion and patients who reported stroke in the past were
considered to have CVD. PAD was deﬁned as surgery or angioplasty of
the arteries supplying the lower extremities in the past or intermittent
claudication or rest pain at inclusion. AAA was deﬁned as present ab-
dominal aortic aneurysm (aortic diameter≥3 cm) or previous AAA sur-
gery. Multiple vascular diseases were deﬁned as having more than 1
vascular disease, possible in any combination. Information on surgical
interventions related to the inclusion criteria was documented. During
a 1-day visit to our medical center, all patients underwent an MRI of
the brain, physical examination, ultrasonography of the carotid arteries,
and blood sampling. Risk factors, medical history, and medication use
were assessed with questionnaires. Between January 2006 and May
2009, follow-up measurements took place including MRI of the brain.
In the period between baseline and follow-up measurements, patients
received a questionnaire every six months to provide information on
hospitalization and outpatient clinic visits. If a cardiovascular event or
surgical intervention was reported, original source documents were re-
trieved and reviewed to determine the occurrence of cardiovascular dis-
ease and related surgical interventions. All possible events and surgical
interventions were audited independently by three physicians.
The SMART-MR study was approved by the ethics committee of our
institution and written informed consent was obtained from all partici-
pants [2].
2.2. Magnetic resonance protocol and brain segmentation
At baseline and follow-up, the MR investigations were performed on
a 1.5 T whole-body system (Gyroscan ACS-NT, Philips Medical Systems,
Best, The Netherlands). The protocol consisted of transversal T1-
weighted (repetition time [TR]/echo time [TE], 235/2 ms), T2-weighted
(TR/TE, 2200/11 ms and 2200/100 ms), fast ﬂuid-attenuated inversion
recovery (FLAIR; TR/TE/inversion time [TI], 6000/100/2000 ms), and in-
version recovery (IR; TR/TE/TI, 2900/22/410 ms) sequences (ﬁeld of
view, 230 × 230 mm; matrix size, 180 × 256; slice thickness, 4.0 mm;
no gap; 38 slices) [2].
The T1-weighted gradient-echo, inversion recovery and FLAIR se-
quence were used for brain segmentation. The probabilistic segmenta-
tion technique has been described previously [13]. The segmentation
program distinguishes cortical gray matter, white matter, sulcal and
ventricular cerebrospinal ﬂuid (CSF), and lesions. The results of the seg-
mentation analysis were visually checked for the presence of infarcts
and adapted if necessary tomake a distinction betweenwhitematter le-
sions (WMLs) and infarct volumes.
2.3. Brain atrophy
At baseline and follow-up, total brain volume was calculated by
summing the volumes of gray and white matter and, if present, the vol-
umes of WML and infarcts. All volumes cranial to the foramenmagnum
were included. As a result, the total brain volume includes both the
hemispheres, brainstem, and cerebellum. Total intracranial volume
(ICV) was calculated by summing the total brain volume and the vol-
umes of the sulcal and ventricular CSF. Total brain, cortical gray matter,
and ventricular volumes were normalized for ICV and expressed as
brain parenchymal fraction (BPF), cortical gray matter fraction (GMF),
and ventricular fraction (VF) [2]. Change in BPF, GMF, and VF wereused as indicators of progression of global, cortical, and subcortical
brain atrophy.
2.4. White matter lesions and infarcts
At baseline and follow-up, thewhole brain was visually searched for
infarcts by a trained investigator and a neuroradiologist, blinded to the
history and diagnosis of the patient. Discrepancies in rating were re-
evaluated in a consensus meeting. Infarcts were deﬁned as focal
hyperintensities on T2-weighted images of at least 3 mm in diameter.
Infarcts located in the white matter also had to be hypointense on T1-
weighted and FLAIR images in order to distinguish them fromWML. Di-
lated perivascular spaces were distinguished from infarcts on the basis
of their location, form, and the absence of gliosis [14]. The location, af-
fected ﬂow territory and type were scored for every infarct. Brain in-
farcts were categorized as cortical infarcts, large subcortical infarcts,
lacunar infarcts, and infratentorial infarcts. We deﬁned large subcortical
infarcts as infarcts sized N15 mm and not conﬂuent with cortical in-
farcts. Lacunar infarcts were deﬁned as infarcts sized 3–15 mm in diam-
eter and located in the subcortical white matter, thalamus, or basal
ganglia. Infratentorial infarcts were located in the brainstem or cerebel-
lum. Volumes of periventricular and deepWMLwere summed to obtain
the total volume of WML. Periventricular lesions were deﬁned as WML
adjacent to or within 1 cm of the lateral ventricles in both hemispheres
and deep lesions were located in the deep white matter tracts and may
or may not have adjoined periventricular lesions [2]. WML volumes
were natural log transformed at baseline and follow-up, because they
were not normally distributed.
2.5. Vascular screening
During the patient's visit to the medical center, an overnight fasting
blood sample was taken to determine glucose and lipid levels. Height
and weight were measured without shoes and heavy clothing, and the
body mass index (BMI) was calculated (kg/m2). Systolic and diastolic
blood pressures (mmHg) were measured twice with a sphygmoma-
nometer and the average of the two measures was calculated. Diabetes
mellitus at baseline was deﬁned as a referral diagnosis of diabetes
mellitus, self-reported diabetes mellitus (use of glucose-lowering
agents), glucose≥11.1 mmol/L, or a knownhistory of diabetesmellitus.
Among subjectswithout a history of diabetesmellitus, butwith a fasting
plasma glucose ≥7.0 mmol/L at baseline, those receiving treatment
with glucose-lowering agents within 1 year after baseline were consid-
ered as having diabetes mellitus at baseline. Hyperlipidemia was de-
ﬁned as total cholesterol N5.0 mmol/L, low-density lipoprotein
cholesterol N3.2 mmol/L, or self-reported use of lipid-lowering drugs.
Smoking habits and alcohol intake were assessed with questionnaires.
Pack years of smoking were calculated and alcohol intake was catego-
rized as never, former, or current. Patientswhohad quit drinking during
the past yearwere assigned to the category current alcohol use. Ultraso-
nography was performed tomeasure the intima-media thickness (IMT)
(mm) in the left and right common carotid arteries, represented by the
mean value of six measurements [7].
2.6. Study sample
At baseline, 1309 patients participated in the baseline examination.
The median interval between index cardiovascular event and MRI
scan was 3.3 months (10th–90th percentile: 1.4–9.8 months). For pa-
tients whowere recruited after an acute stroke (n = 40), median inter-
val between event and participation was 3.6 months, with a 10th–90th
percentile of 1.1 and 10.1 months. Of these 1309 patients, 19 had no
MRI, and 14had no FLAIR sequence. In addition, in 44 patients brain vol-
ume data were missing due to motion or artifacts. As a result, baseline
MRI data were available in 1232 patients.
Table 1
Baseline characteristics of the study sample (n = 663) per age category.
Age categories
b55 years, 55–64 years, ≥65 years,
n = 257 n = 244 n = 162
Age (years) 48 ± 5 59 ± 3 70 ± 4
Sex, % men 81 82 81
Vascular disease location, %
Coronary artery disease 56 52 44
Cerebrovascular disease 14 15 19
Peripheral arterial disease 14 14 7
Abdominal aortic aneurysm 2 4 4
Multiple vascular diseases 8 13 19
Cardiovascular risk factors
BMI (kg/m2) 27 ± 4 27 ± 4 26 ± 3
Smoking (pack years)a 22 (0, 46) 21 (0, 54) 14 (0, 55)
Alcohol intake, % current 77 82 76
Systolic BP (mmHg) 134 ± 18 142 ± 19 147 ± 22
Diastolic BP (mmHg) 82 ± 10 82 ± 10 80 ± 11
Hyperlipidemia, % 82 75 76
Diabetes mellitus, % 9 14 20
IMT (mm) 0.8 ± 0.2 1.0 ± 0.4 1.0 ± 0.3
Brain volumes (% ICV)
Brain parenchymal fraction 80.8 ± 2.0 79.2 ± 2.3 77.2 ± 2.4
Cortical gray matter
fraction
37.7 ± 3.1 35.8 ± 3.0 34.7 ± 3.1
Ventricular fraction 1.7 ± 0.7 2.0 ± 0.7 2.6 ± 0.9
Total WML volume
fractiona
0.07 (0.02, 0.22) 0.11 (0.03, 0.33) 0.18 (0.04, 0.90)
Cerebrovascular pathology, %
Any infarct 20 28 37
Cortical 9 13 13
Large subcortical 1 0 1
Lacunar 11 17 27
Infratentorial 5 5 8
Cerebellum 4 3 6
Brainstem 2 3 3
Characteristics presented as mean ± SD, unless stated otherwise.
Percentage of missing values before imputation: BMI 0.2%, smoking 0.3%, alcohol intake
0.5%, hyperlipidemia 1.8%, IMT 2.0%, cortical graymatter fraction 17.5%, all other variables
0.0%.
a Median (10th–90th percentile).
114 P.H. van der Veen et al. / Journal of the Neurological Sciences 337 (2014) 112–118At follow-up, all patients were invited in the same order as they
were included at baseline, so that every patient had a follow-up exam-
ination after a median (interquartile range) follow-up period of 3.8
(3.7–4.1) years. Due to logistics and MRI capacity, it was not possible
to have an exact follow-up period of 4 years for every patient. Of 1232
patients, 718 patients participated in the follow-up examination. Of
these, 38hadnoMRI, and in 17patients brain volumedataweremissing
due to motion or artifacts. Due to a temporary change in theMRI proto-
col, the IR sequence wasmissing in 116 patients and not adequate in 20
patients. This resulted in missing data on cortical gray matter in these
136 patients, as the IR sequence was obligatory for cortical gray matter
segmentation. For segmentation of the other brain volumes, it was pos-
sible to only use the FLAIR sequence [7,13]. As a result, the analyses on
the prospective data were performed in 663 patients.
Our sample (n = 663) was younger, more often male, had more
CAD and less PAD andmultiple vascular diseases, had lower blood pres-
sure levels, less often diabetesmellitus, and had less cerebrovascular le-
sions on MRI than the 569 patients who did not participate in the
follow-up examination.
2.7. Data analyses
We usedmultiple imputation (10 datasets) using the statistical pro-
gram R (aregImpute; version 2.10.0) to address missing values in the
study sample of 663 patients. Data were analyzed using SPSS version
20.0 (Chicago, IL, USA), by pooling the 10 imputed datasets [15].
First, baseline characteristicswere calculated for the total study pop-
ulation and according to 3 age groups (b55 years, 55–64 years, and
≥65 years) and sex. Second, linear regression analysis was used to esti-
mate the association of age (continuous and in 3 groups) and sex with
change in BPF, GMF, VF, and WML volume. Logistic regression analysis
was used to estimate the association of age and sex with any new
brain infarct (all, cortical, and lacunar). New brain infarcts were calcu-
lated by subtracting the number of infarcts at baseline from the number
of infarcts at follow-up. This number of infarcts was dichotomized for
analysis as no new infarcts (≤0) and ≥1 new infarcts at follow-up.
The respective brainMRImeasures at follow-upwere entered as depen-
dent variable and age, sex, duration of follow-up period, and baseline
brain MRI measures were entered as independent variables (model 1).
When progression of brain atrophywas the outcome, additional adjust-
ments were made for baseline brain infarcts and WML volume; when
progression of WML was the outcome, additional adjustments were
made for baseline brain infarcts and BPF; when new brain infarcts
were the outcome, additional adjustments were made for baseline
WML and BPF (model 2). Furthermore, in model 3 additional adjust-
ments weremade for cardiovascular risk factors (BMI, smoking, alcohol
use, systolic and diastolic blood pressure, hyperlipidemia, diabetes
mellitus, intima-media thickness).
To assess whether progression of brain atrophy or cerebrovascular
lesions accelerated with age, quadratic age-terms were entered to
model 1. To investigate whether the rate of progression of brain MRI
outcomes associated with age differed for men and women, analyses
were repeated across strata of sex and interaction terms between age
and sex were added to the regression models (model 1).
Finally, to investigate the association of vascular disease categories
(CAD, CVD, PAD, AAA, or multiple vascular diseases) with progression
of brain atrophy or cerebrovascular lesions, these categories were
added to model 1. Patients with CAD were used as the reference
category.
3. Results
Themean (SD, range) age of the populationwas 57 (9, 28–79) years
and 81% were men. Table 1 shows baseline characteristics across 3 age
groups and for men and women, see Supplemental Table 1.After a median (interquartile range) follow-up period of 3.8 (3.7–
4.1) years, the mean (SD) decrease in BPF and GMF was 0.98 (1.08)%
ICV and 1.72 (2.17)% ICV, and the mean (SD) increase in VF was 0.19
(0.28)% ICV (Supplemental Table 2). The mean WML volume increase
was 0.06% ICV, ranging from 0.01% ICV in the youngest age group to
0.13% ICV in the oldest age group, and 82 patients (12% of 663) had
one or more new brain infarcts; 3% was due to new cortical infarcts,
9% to new lacunar infarcts, and 1% to new infratentorial infarcts. One
new large subcortical infarct was observed (Supplemental Table 2).
Forty-four percent of the new brain infarcts were silent.3.1. Age and sex
Older agewas associatedwithmore progression of brain atrophy and
cerebrovascular lesions during follow-up (Table 2). Themean differences
in change (95% CI) in BPF, GMF, and VF between older (≥65 years)
and younger patients (b55 years) were −1.20 (−1.43; −0.97)%
ICV,−1.58 (−2.07;−1.10)% ICV, and 0.19 (0.14; 0.25)% ICV. In younger
patients, change in natural log transformedWML volumewas negative:
mean difference in change (95% CI) was−0.16 (−0.25;−0.08)% ICV.
However, with increasing age, natural log transformedWMLvolume in-
creased, irrespective of other baseline brain MRI measures and cardio-
vascular risk factors (Table 2, models 2 and 3).
Older patients also showed a fourfold increased risk of new brain
infarcts (Table 2, model 1), but this could partly be explained by WML
Table 2
Progression ofmeasures of brain atrophy and cerebrovascular lesions onMRI after on average 3.9 years of follow-up in663patientswithmanifest arterial disease according to categories of
age, sex, and vascular disease location.
Model N Change in BPF,
B (95% CI)a
Change in GMF,
B (95% CI)a
Change in VF,
B (95% CI)a
Change in WML,
B (95% CI)a
New brain infarcts,
OR (95% CI)b
Age
b55 years, referencec 257 0 0 0 0 1.0
55–64 years 1 244 −0.50 (−0.68;−0.32)⁎⁎ −0.74 (−1.16;−0.33)⁎⁎ 0.11 (0.07; 0.16)⁎⁎ 0.30 (0.19; 0.42)⁎⁎ 1.67 (0.86–3.23)
2 −0.48 (−0.66;−0.30)⁎⁎ −0.65 (−1.05;−0.25)⁎⁎ 0.10 (0.05; 0.14)⁎⁎ 0.30 (0.18; 0.42)⁎⁎ 1.23 (0.61–2.49)
3 −0.47 (−0.66;−0.28)⁎⁎ −0.72 (−1.16;−0.28)⁎⁎ 0.09 (0.04; 0.14)⁎⁎ 0.28 (0.16; 0.41)⁎⁎ 1.08 (0.51–2.28)
≥65 years 1 162 −1.20 (−1.43;−0.97)⁎⁎ −1.58 (−2.07;−1.10)⁎⁎ 0.19 (0.14; 0.25)⁎⁎ 0.59 (0.45; 0.73)⁎⁎ 3.99 (2.09–7.61)⁎⁎
2 −1.15 (−1.38;−0.92)⁎⁎ −1.35 (−1.83;−0.88)⁎⁎ 0.16 (0.11; 0.22)⁎⁎ 0.59 (0.43; 0.74)⁎⁎ 1.70 (0.77–3.75)
3 −1.13 (−1.37;−0.88)⁎⁎ −1.39 (−1.94;−0.85)⁎⁎ 0.14 (0.08; 0.20)⁎⁎ 0.57 (0.40; 0.73)⁎⁎ 1.50 (0.69–3.27)
Sex
Women, referencec 124 0 0 0 0 1.0
Men 1 539 −0.25 (−0.44;−0.06)⁎ −0.94 (−1.35;−0.52)⁎⁎ 0.02 (−0.03; 0.07) −0.02 (−0.15; 0.11) 2.66 (1.17–6.06)⁎
2 −0.27 (−0.47;−0.08)⁎⁎ −1.02 (−1.44;−0.60)⁎⁎ 0.04 (−0.01; 0.09) −0.02 (−0.16; 0.11) 3.03 (1.28–7.14)⁎
3 −0.32 (−0.52;−0.12)⁎⁎ −1.10 (−1.53;−0.67)⁎⁎ 0.04 (−0.01; 0.09) −0.03 (−0.17; 0.11) 3.24 (1.33–7.92)⁎
Vascular disease location
CAD, referencec 342 0 0 0 0 1.0
CVD 1 105 −0.20 (−0.41; 0.02) −0.67 (−1.13;−0.20)⁎ 0.11 (0.05; 0.16)⁎⁎ 0.09 (−0.06; 0.24) 2.40 (1.18–4.89)⁎
2 0.00 (−0.24; 0.24) −0.13 (−0.64; 0.39) 0.08 (0.02; 0.14)⁎ −0.03 (−0.19; 0.14) 2.15 (1.01–4.58)⁎
3 −0.03 (−0.27; 0.21) −0.18 (−0.70; 0.33) 0.09 (0.03; 0.15)⁎⁎ −0.03 (−0.20; 0.13) 2.20 (1.00–4.82)
PAD 1 80 −0.18 (−0.42; 0.06) −0.63 (−1.15;−0.12)⁎ 0.04 (−0.02; 0.10) −0.09 (−0.25; 0.08) 1.42 (0.59–3.42)
2 −0.15 (−0.38; 0.09) −0.53 (−1.04;−0.02)⁎ 0.03 (−0.03; 0.09) −0.11 (−0.27; 0.06) 1.40 (0.57–3.44)
3 −0.14 (−0.38; 0.10) −0.63 (−1.16;−0.10)⁎ 0.03 (−0.03; 0.09) −0.07 (−0.24; 0.09) 1.06 (0.40–2.78)
AAA 1 21 −0.02 (−0.45; 0.40) 0.26 (−0.67; 1.19) 0.13 (0.02; 0.24)⁎ 0.07 (−0.22; 0.37) 3.99 (1.41–11.27)⁎
2 0.03 (−0.40; 0.45) 0.40 (−0.52; 1.31) 0.11 (0.01; 0.22)⁎ 0.05 (−0.24; 0.34) 2.99 (0.97–9.23)
3 0.02 (−0.41; 0.45) 0.46 (−0.46; 1.39) 0.11 (−0.00; 0.21) 0.06 (−0.24; 0.36) 3.05 (0.94–9.90)
Multiple 1 84 −0.08 (−0.32; 0.15) −0.24 (−0.75; 0.26) 0.02 (−0.04; 0.08) 0.10 (−0.06; 0.26) 0.89 (0.39–2.05)
2 0.06 (−0.18; 0.31) 0.16 (−0.37; 0.68) −0.00 (−0.07; 0.06) 0.02 (−0.15; 0.19) 0.73 (0.30–1.77)
3 0.07 (−0.18; 0.32) 0.11 (−0.43; 0.64) −0.02 (−0.08; 0.05) 0.03 (−0.15; 0.20) 0.63 (0.26–1.57)
Model 1: adjusted for age (not if age was independent variable), sex (not if sex was independent variable), baseline measurement of brain structure, and follow-up period.
Model 2: BPF, GMF, VF, model 1 + lacunar and non-lacunar infarcts onMRI andWML;WML, model 1 + lacunar and non-lacunar infarcts onMRI and BPF; brain infarcts, model 1 + BPF
and WML.
Model 3: model 2 + systolic and diastolic blood pressure, diabetes mellitus, body mass index, alcohol use, pack years, hyperlipidemia, intima-media thickness.
BPF = brain parenchymal fraction; GMF = cortical gray matter fraction; VF = ventricular fraction; WML = natural log transformed white matter lesion volume (% ICV);
CI = conﬁdence interval; OR = odds ratio; CAD = coronary artery disease; CVD = cerebrovascular disease; PAD = peripheral arterial disease; AAA = abdominal aortic aneurysm.
a B represents % change in BPF, GMF, VF, and natural log transformed WML (as % of ICV) in comparison with the reference category after 3.9 ± 0.4 years of follow-up.
b OR for new brain infarcts, which were deﬁned as change in number of infarcts of ≥1 infarct in comparison with the reference category after 3.9 ± 0.4 years of follow-up.
c Change in brain volumes for reference categories:
Age, b55 years: BPF−0.50 (−0.63;−0.37), GMF−1.06 (−1.36;−0.77), VF 0.10 (0.07; 0.13), WML−0.16 (−0.25;−0.08);
Sex, women: BPF−0.78 (−0.95;−0.61), GMF−0.96 (−1.35;−0.57), VF 0.17 (0.13; 0.22), WML 0.11 (−0.01; 0.23);
Vascular disease category, CAD: BPF−0.90 (−1.01;−0.80), GMF−1.50 (−1.73;−1.26), VF 0.16 (0.13; 0.19), WML 0.08 (0.01; 0.15).
⁎ p b 0.05.
⁎⁎p b 0.005.
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and 3). Furthermore, age-squared was associated with decreases in
BPF (p = 0.08) andGMF (p = 0.03) over time, indicating that the atro-
phy tended to accelerate with older age.
Comparedwithwomen,men showed a larger age-adjusted decrease
in BPF and GMF over time: mean differences in change (95% CI)
between men and women were −0.25 (−0.44; −0.06)% ICV and
−0.94 (−1.35; −0.52)% ICV (Table 2, model 1). These differences
in BPF and GMF were irrespective of other baseline brain MRI mea-
sures (model 2: −0.27 (−0.47; −0.08)% ICV and −1.02 (−1.44;
−0.60)% ICV) and cardiovascular risk factors (model 3:−0.32 (−0.52;
−0.12)% ICV and −1.10 (−1.53; −0.67)% ICV). Men also showed
more new brain infarcts, particularly new lacunar infarcts (Table 2 and
Supplemental Table 3). Similar risk estimates were shown in model 2
and 3 (model 2: OR = 3.03, 95% CI 1.28–7.14 and OR = 3.60, 95% CI
1.20–10.80, respectively and model 3: OR = 3.24, 95% CI 1.33–7.92 and
OR = 3.29, 95% CI 1.84–5.86, respectively). No differences between
men and women were observed with respect to change in VF or WML
volume over time (Table 2).
A signiﬁcant interaction between age and sex was present for
change in GMF (p = 0.02). Stratiﬁed analyses showed that with older
age, men had a larger decrease in GMF thanwomen (Fig. 1b). This inter-
action was not observed for BPF, VF, or WML (Fig. 1a, c, d).3.2. Vascular disease
Comparedwith patients with CAD, patients with CVD showed larger
decrease in GMF and larger increase in VF during follow-up after
adjusting for age and sex; mean differences in change (95% CI) were
−0.67 (−1.13; −0.20)% ICV and 0.11 (0.05; 0.16)% ICV (Table 2,
model 1). The relation between CVD and VF showed similar effect esti-
mates inmodels 2 and 3 (model 3: 0.09 (0.03; 0.15)% ICV), but the effect
estimates for the relation between CVD and GMF diminished and
were no longer signiﬁcant after further adjustments (model 3:−0.18
(−0.70; 0.33)% ICV). CVD patients showed more new brain infarcts and
in particular new cortical infarcts (Table 2 and Supplemental Table 3).
In models 2 and 3, these risk estimates only marginally changed.
Patients with PAD showed a larger age and sex-adjusted decrease in
GMF over time thanpatientswith CAD (mean difference in change (95%
CI):−0.63 (−1.15;−0.12)% ICV (Table 2, model 1)), and this was irre-
spective of baseline cerebrovascular lesions and cardiovascular risk fac-
tors (model 3:−0.63 (−1.16;−0.10)% ICV).
Furthermore, AAA patients showed a signiﬁcantly larger increase in
VF than patients with CAD after adjusting for age and sex; mean differ-
ence in change (95% CI) was 0.13 (0.02; 0.24)% ICV (Table 2, model 1).
However, this was partly explained by cardiovascular risk factors
(model 3). Patients with AAA also showed more new brain infarcts
Fig. 1. Longitudinal relation between age and change in total brain (a), cortical graymatter (b), ventricular (c), and whitematter lesion volume (natural log transformed) (d) for men and
women separately. Bars represent the mean (standard error) adjusted change in brain volume after on average 3.9 years of follow-up. Adjusted for baselinemeasurement of brain struc-
ture and follow-up period. ICV = intracranial volume.
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mental Table 3). However, these ﬁndings were partly explained by
WML volume, total brain volume, and cardiovascular risk factors
(model 3: OR = 3.05, 95% CI 0.94–9.90 and OR = 6.98, 95% CI 1.03–
47.52).
Patients with multiple vascular diseases showed no difference in
change in brain volumes or progression of any infarct when compared
with CAD patients.
Additional analyses were performed to studywhether the accrual of
new brain infarcts or WML volume change altered the associations,
whether new vascular events during follow-up were of inﬂuence, and
whether treatment effect was an issue in this study. First, progression
of brain infarcts and WML volume was added to model 1. Results
showed that the observed associations somewhat attenuated, but
remained statistically signiﬁcant (Supplementary Table 4, model 4).
Second, new vascular events during follow-up were added to model
3. Results showed no signiﬁcant change in the effect estimates of the
found associations (Supplementary Table 4, model 5).
Third, to study a possible treatment effect, analyseswere repeated in
a subset of the study population who had not undergone a surgical in-
tervention prior to inclusion in the study (n = 170, 26%) and the effect
estimates of the associations of age and sex with changes in brain vol-
umes and risk of new brain infarcts were similar (Supplementary
Table 5). However, due to loss of power, we were not able to study a
possible treatment effect on the associations of vascular disease catego-
rieswith brain changes in this subset. Also, we additionally adjusted the
analyses for surgical interventions during follow-up for the total study
population (n = 663) (Supplementary Table 4, model 6) and the effect
estimates shown in Table 2 did not materially change.
Finally, since post-stroke focal brain atrophy can contribute to the
progression of brain atrophy in this population, we performedsensitivity analyses excluding 15 patients who were recruited within
90 days after an acute stroke, and the results did not materially change.
4. Discussion
Within a large cohort of patientswith variousmanifestations of arte-
rial disease, we observed progression of global, cortical, and subcortical
brain atrophy over 3.9 years of follow-up. With older age, progression
of global and cortical atrophy tended to accelerate and was stronger in
men than in women. Our results are in line with population-based lon-
gitudinal studies reporting annual gross brain volume decreases in the
order of 0.2–0.6%, depending on the age of the cohort [9–11,16]. Com-
pared with our cross-sectional ﬁndings [2], changes in BPF and GMF
are larger in our longitudinal analyses. This ﬁnding is in contrast with
results in some earlier studies [9,10,17], but conﬁrmed in at least one
other study [11]. Although there is no evident explanation for the differ-
ence in our cross-sectional and longitudinal ﬁndings, issues related to
survival, non-response, or cohort effects might all have contributed to
this difference.
Our ﬁnding that with older age, men showed more progression of
cortical atrophy than women is in line with our cross-sectional ﬁndings
[2] and other studies [11,18,19], although not all [17,20,21]. This ﬁnding
may be explained by theﬁnding that comparedwithwomen,menmore
often had an unfavorable cardiovascular risk proﬁle in our study popu-
lation. However, adjusting for these cardiovascular risk factors did not
explain the difference in progression of brain atrophy. In addition, it
has also been suggested that sex hormones or differences in regional
brain metabolism between men and women might play a role in brain
atrophy, but the exact mechanisms are not entirely clear [19].
In younger patients, we observed regression ofWML volume, which
was somewhat surprising. An explanation for the negative change in
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brain atrophy of the surrounding tissue or due to a nearby infarct.
Other explanations are measurement error, since the WML volumes at
baselinewere already quite small, or resolution ofWMLs. Earlier studies
have suggested that WMLs are not irreversible [22,23]. In addition, we
observed progression of WML volume with age, which was similar for
men and women. Other longitudinal studies who used volumetric as-
sessment of change inWML volume reported similar [11] or somewhat
larger changes in WML volume [24,25]. However, these studies were
performed in smaller and older samples of the general population and
the results may therefore be not fully comparable.
The risk of new brain infarcts also increasedwith age andwas stron-
ger in men than in women, particularly for new lacunar infarcts. This
ﬁnding is in contrast with our cross-sectional ﬁndings and the results
from a population-based longitudinal study on new brain infarcts,
where there were no signiﬁcant sex differences [2,26]. Additionally,
for lacunar infarcts, a cross-sectional study in the general population
showed a higher risk for women instead of men [27], while another
population-based study did not [28]. These inconsistent ﬁndings make
it difﬁcult to explain the association of new brain infarcts withmale sex.
With respect to the different vascular disease locations, we found
that, comparedwith CADpatients, patientswith CVDhadmore progres-
sion of cortical and subcortical atrophy, and more new brain infarcts, in
particular new cortical brain infarcts. However, the association with
progression of cortical atrophy was partly explained by the presence
of cerebrovascular lesions, such as brain infarcts and WMLs.
PAD patients had more progression of cortical atrophy compared
with patients with CAD. These ﬁndings were independent of the pres-
ence of cardiovascular risk factors at baseline. Although we know that
when manifest arterial disease is present in one vascular bed, there is
an increased risk for developingmanifest arterial disease in other vascu-
lar beds [29], ourﬁndings suggest thatmanifest arterial disease at differ-
ent locationsmight differentially inﬂuence progression of brain atrophy
and cerebrovascular lesions. Earlier studies relating arterial disease to
progression of brain pathology only evaluated patients with vascular
disease present in one vascular bed. Presence of carotid atherosclerosis
has been associated with increased risk of new brain infarcts, WMLs,
and progression of brain atrophy [7,23,30]. Although there is little evi-
dence on the relation between peripheral and abdominal atherosclero-
sis and progression of brain pathology, one cross-sectional study
showed that aortic atherosclerosis was associated with more WMLs
[31]. The possible differential effect of the location of arterial disease
on progression of brain atrophy and/or cerebrovascular lesions could
be explained by differences in cardiovascular risk factors or differences
in treatment strategies between the vascular disease categories. We
could only partly account for these possible differences by adjusting
for baseline risk factors, but additional analyses suggested that our re-
sults could not be explained by treatment effects prior or during
follow-up. Also, differences in hemodynamics, remodeling properties,
and/or underlying arterial wall structure of the different vascular beds
could play a role in the differential effect of the location of arterial dis-
ease on progression of brain atrophy and/or cerebrovascular lesions
[32].
To our knowledge, our study is the ﬁrst to prospectively examine
brain changes on MRI in a large cohort of well-deﬁned patients with
various manifestations of arterial disease. Other unique aspects of this
study are the wide age range of the population and the availability of
brain volumetric measurements on MRI at baseline and follow-up.
This made it possible to differentiate between the different brain tissues
and to obtain relatively precise estimates of progression of brain atro-
phy and cerebrovascular lesions.
Limitations of this study are, ﬁrst, that individuals who participated
in the follow-up examination represented a relatively healthy group.
This may have led to an underestimation of the progression of brain at-
rophy and cerebrovascular lesions. Second, the number of new brain in-
farcts was relatively small, especially new cortical and lacunar infarcts.This resulted in reduced power and the associations found in this
study should therefore be interpreted with caution. Third, patients
were classiﬁed in ﬁve distinct vascular disease categories according to
patient history and inclusion criteria at baseline. Vascular events that
took place in the follow-up period were, however, not included in the
category deﬁnition. However, we did perform additional analyses
adjusting for vascular events during follow-up and the results did not
change.
In conclusion, in a large cohort of patients with various manifesta-
tions of arterial disease, we observed trends in accelerated progression
of brain atrophy and progression of cerebrovascular lesions, especially
in older men and patients with CVD or PAD.
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